You're describing a chemical compound that goes by the systematic name **2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide**, or more simply, **6-[(2-Morpholinoethyl)carbamoyl]pyrimidine-2,4(1H,3H)-dione**. This is a complex organic molecule, and its importance lies in its potential therapeutic applications.
Here's a breakdown of its components and why it's of interest to researchers:
* **Pyrimidine-2,4(1H,3H)-dione:** This is the core structure of the molecule. It's a modified pyrimidine ring system, with two carbonyl groups (C=O) attached. Pyrimidines are fundamental building blocks of DNA and RNA, making them important for biological processes.
* **6-[(2-Morpholinoethyl)carbamoyl]:** This portion is attached to the pyrimidine ring. It contains a morpholine ring, which is a common heterocyclic structure in pharmaceuticals. The carbamoyl group is an amide linkage that connects the morpholine to the pyrimidine.
This combination of structural features suggests that the compound might have interesting biological activity.
**Potential Research Significance:**
* **Anti-cancer activity:** The compound might exhibit anticancer activity by targeting specific enzymes or pathways involved in cancer cell growth and proliferation. Pyrimidine derivatives are known to have anti-cancer properties.
* **Anti-inflammatory activity:** The morpholine moiety is often associated with anti-inflammatory effects, which might make this compound useful in treating inflammatory conditions.
* **Other pharmacological activities:** It's possible that this compound might have other therapeutic applications, such as antibacterial or antiviral activities.
**Important Note:** It's crucial to emphasize that this information is based on the compound's structure and its potential for activity. The exact biological effects and mechanisms of action of this specific molecule need to be thoroughly investigated through research. Further studies, including preclinical and clinical trials, are necessary to assess its safety and efficacy before it can be considered for therapeutic use.
ID Source | ID |
---|---|
PubMed CID | 2149976 |
CHEMBL ID | 1330642 |
CHEBI ID | 109275 |
Synonym |
---|
MLS000103721 |
smr000018146 |
CHEBI:109275 |
HMS1654P10 |
AB00676167-01 |
2-(2,4-dioxo-1h-pyrimidin-6-yl)-n-(2-morpholin-4-ylethyl)acetamide |
F1811-0096 |
868228-80-2 |
2-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-n-(2-morpholinoethyl)acetamide |
HMS2242B19 |
CHEMBL1330642 |
AKOS024610512 |
Q27188354 |
2-(2,4-dioxo-1h-pyrimidin-6-yl)-n-[2-(4-morpholinyl)ethyl]acetamide |
sr-01000015790 |
SR-01000015790-1 |
Class | Description |
---|---|
pyrimidone | A pyrimidine carrying one or more oxo substituents. |
morpholines | Any compound containing morpholine as part of its structure. |
tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 21.1613 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 21.1613 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 1,000.0000 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 7.9433 | 0.0072 | 15.7588 | 89.3584 | AID411 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 10.2663 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 17.7828 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Integrin beta-3 | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 12.5893 | 0.3162 | 11.4157 | 31.6228 | AID924 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |